Metabolites, Volume 11, Issue 12
2021 December - 94 articles
Cover Story: Methotrexate remains the cornerstone of disease-modifying therapy in the treatment of rheumatoid arthritis based on its efficacy, toxicity profile, and economic merits. While methotrexate has been proven to slow disease progression, minimizing damage to tissues and joints, it is often characterized by a highly variable response and a delayed onset of action. Approximately two-thirds of patients fail to have an adequate response to methotrexate alone and will require additional therapies, such as biologics. This study evaluates changes in the plasma metabolome associated with response to methotrexate in rheumatoid arthritis over a 16-week treatment period with the goal of understanding the metabolic basis for methotrexate efficacy and toward the identification of potential metabolic biomarkers of methotrexate response. View this paper. - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.